Cocrystal Pharma, Inc. (COCP) Form 10-Q — May 15, 2026
Cocrystal Pharma reported a net loss of $2.3 million for the first quarter of 2026, driven by $1.4 million in R&D expenses and $1.2 million in G&A costs, partially offset by $225,000 in grant income from an NIH award. The company disclosed substantial doubt about its ability to continue as a going concern, noting that its $4.7 million in cash and restricted cash is insufficient to fund operations beyond the next 12 months without additional financing. A significant legal dispute is ongoing with a UK-based CRO regarding a failed Phase 2a influenza study; Cocrystal is seeking a $6.3 million refund or a redo of the study, while the CRO has filed a counterclaim for approximately $600,000.
Key figures
- Revenue
- 225000
- Total Debt
- 0
- Total Assets
- 7426000
- Cash Position
- 4685000
- Ga Expense
- 1210000
- Rd Expense
- 1371000
- Grant Income
- 225000
- Shares Outstanding
- 13787453
- Options Outstanding
- 838351
- Warrants Outstanding
- 7222821
- Arbitration Claim Amount
- 6309000
- Arbitration Counterclaim Amount
- 600000
Price after filing
Close on the filing date to close N calendar days later (from $1.26). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.